# Phase 2a Study of HPG1860 in Subjects With NASH

> **NCT05338034** · PHASE2 · UNKNOWN · sponsor: **Hepagene (Shanghai) Co., Ltd.** · enrollment: 89 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** HPG1860
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05338034
- **Lead sponsor:** Hepagene (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-22
- **Primary completion:** 2023-02
- **Final completion:** 2023-03
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338034, "Phase 2a Study of HPG1860 in Subjects With NASH". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05338034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*